CD8A and neoplasm: The immune response of patients with glioma are characterized by defects in circulating T-cell populations, poor tumor antigen-specific CD8+ T-cell responses, and elevated programmed death 1 (PD-1) in CD8+ T cells contributing to the poor prognosis of these patients (5–9).